Randomized assignment to copper IUD or depot-medroxyprogesterone acetate: feasibility of enrollment, continuation and disease ascertainment

dc.creatorFeldblum, PJ
dc.creatorCaraway, J
dc.creatorBahamondes, L
dc.creatorEl-Shafei, M
dc.creatorHa, DQ
dc.creatorMorales, E
dc.creatorWevill, S
dc.creatorCondon, S
dc.date2005
dc.dateSEP
dc.date2014-11-18T19:31:42Z
dc.date2015-11-26T16:58:08Z
dc.date2014-11-18T19:31:42Z
dc.date2015-11-26T16:58:08Z
dc.date.accessioned2018-03-28T23:45:45Z
dc.date.available2018-03-28T23:45:45Z
dc.identifierContraception. Elsevier Science Inc, v. 72, n. 3, n. 187, n. 191, 2005.
dc.identifier0010-7824
dc.identifierWOS:000231654300006
dc.identifier10.1016/j.contraception.2005.03.006
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/58874
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/58874
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/58874
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1277852
dc.descriptionObjectives: We conducted a feasibility study to enroll and follow family planning acceptors who were randomly assigned to use an intrauterine device (IUD) or injectable depot-medroxyprogesterone acetate (DMPA). Methods: Centers in Brazil, Guatemala, Egypt and Vietnam aimed to enroll 100 participants per site. Enrolled women were randomly assigned to have inserted a TCu 380A IUD, or to receive injections of 150 mg of DMPA every 3 months, and scheduled for up to 12 months of follow-up. We tested for cervical infection at first and final visits, and examined for signs of pelvic inflammatory disease (PID) at each visit. Results: The sites screened 555 women and enrolled 368. Two women (0.5%) had three discomfort signs of PID during follow-up. The prevalence of gonorrhea at each woman's final follow-up visit was 0.5%, and the prevalence of chlamydia at final visit was 5.4%. Sixty-eight percent of women either completed 12 months of observation with their assigned method or were still using their method at the end of the study. Conclusion: A larger, definitive clinical trial appears feasible. The majority of women we approached agreed to participate; nearly 400 women were enrolled; two thirds continued to use their assigned method until study closeout; and the STI risk was moderate. (c) 2005 Elsevier Inc. All rights reserved.
dc.description72
dc.description3
dc.description187
dc.description191
dc.languageen
dc.publisherElsevier Science Inc
dc.publisherNew York
dc.publisherEUA
dc.relationContraception
dc.relationContraception
dc.rightsfechado
dc.rightshttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.sourceWeb of Science
dc.subjectpilot study
dc.subjectrandomized controlled trial
dc.subjectcopper IUD
dc.subjectdepot-medroxyprogesterone acetate
dc.subjectpelvic inflammatory disease
dc.subjectPelvic Inflammatory Disease
dc.subjectIntrauterine-device
dc.titleRandomized assignment to copper IUD or depot-medroxyprogesterone acetate: feasibility of enrollment, continuation and disease ascertainment
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución